153 papers found
Refreshing results…
The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL)
Plasma Microrna Predicts B-Cell Lymphoma up to 12 Months before Diagnosis – Data from the Danish Blood Donor Study
Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10
18F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study
Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma
Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation:Another “double hit” lymphoma with very poor outcome?
Supplementary Material
Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another “double hit” lymphoma with very poor outcome?
Impact of18F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement
Clinical Outcome Determinants for Sequentially Transformed Indolent Lymphomas Treated with or without Autologous Stem Cell Transplantation
Role of Bone Marrow Biopsy in the Staging of Diffuse Large B-Cell Lymphoma in the PET/CT Era
Clinical outcome determinats for sequentially transformed indolent lymphomas treated with or without autologous stem cell transplantation
Plasma Microrna Predicts B-Cell Lymphoma up to 12 Months before Diagnosis:Data from the Danish Blood Donor Study
Evaluation of clinical trial eligibility and prognostic indicies in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry
Prognostic Impact of Extranodal Diffuse Large B-Cell Lymphoma in the Era of Immunochemotherapy and PET/CT Staging
Incidence and Predictors Of Venous Thromboembolism Among Lymphoma Patients In Denmark: A Nationwide Population-Based Cohort Study
Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Ofa First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. An updated analysis with 5 years median follow-up of the population-based investigation from the Danish Lymphoma Group
Real world data on primary treatment for mantle cell lymphoma 2000-2011 - a Nordic Lymphoma Group observational study
Missing publications? Read more about our data sources.